Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.43 |
| ▸ | NPC1 | O15118 | 5/20 | 0.43 |
| ▸ | RAB9A | P51151 | 5/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17996529 | 1.00 | HTR2C (0.51) | HTR2CALDH1A1MEN1KMT2ANPSR1 | |
| SCHEMBL19403459 | 1.00 | HTR2C (0.51) | HTR2CALDH1A1MEN1KMT2ANPSR1 | |
| SCHEMBL12405637 | 0.87 | HTR2C (0.46) | HTR2CALDH1A1MEN1KMT2ANPSR1 | |
| SCHEMBL1568398 | 0.84 | HTR2C (0.48) | HTR2CALDH1A1MEN1KMT2ANPSR1 | |
| SCHEMBL1568401 | 0.84 | HTR2C (0.48) | HTR2CALDH1A1MEN1KMT2ANPSR1 | |
| SCHEMBL12405638 | 0.84 | HTR2C (0.52) | HTR2CALDH1A1MEN1KMT2ANPSR1 | |
| SCHEMBL21978129 | 0.84 | HTR2C (0.52) | HTR2CALDH1A1MEN1KMT2ANPSR1 | |
| SCHEMBL8749775 | 0.82 | HTR2C (0.51) | HTR2CALDH1A1MEN1KMT2ANPSR1 | |
| SCHEMBL2156734 | 0.82 | HTR2C (0.51) | HTR2CALDH1A1MEN1KMT2ANPSR1 | |
| SCHEMBL1568616 | 0.82 | HTR2C (0.46) | HTR2CALDH1A1MEN1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4658667-A1 | CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY | Merck Sharp & Dohme LLC (US) | 2025-12-10 | — | — | EP | disclosed |
| WO-2024163691-A1 | CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY | MERCK SHARP & DOHME LLC (US) | 2024-08-08 | — | — | WO | disclosed |
| US-10220039-B2 | Method of treating polycystic kidney diseases with ceramide derivatives | GENZYME CORPORATION (US) | 2019-03-05 | — | — | US | disclosed |
| EP-2550965-B1 | Ceramide derivatives for treating polycystic kidney disease | GENZYME CORP (US) | 2019-01-16 | — | — | EP | disclosed |
| EP-2209473-B1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | GENZYME CORP (US) | 2017-11-22 | — | — | EP | disclosed |
| US-20170258802-A1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | GENZYME CORPORATION | 2017-09-14 | — | — | US | disclosed |
| US-20170258802-A1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | GENZYME CORPORATION | 2017-09-14 | — | — | US | disclosed |
| US-20150216872-A1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | GENZYME CORPORATION | 2015-08-06 | — | — | US | disclosed |
| US-20150216872-A1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | GENZYME CORPORATION | 2015-08-06 | — | — | US | disclosed |
| US-8912177-B2 | Method of treating polycystic kidney diseases with ceramide derivatives | GENZYME CORPORATION (US) | 2014-12-16 | — | — | US | disclosed |
| US-8912177-B2 | Method of treating polycystic kidney diseases with ceramide derivatives | GENZYME CORPORATION (US) | 2014-12-16 | — | — | US | disclosed |
| EP-2550965-A2 | Ceramide derivatives for treating polycystic kidney disease | GENZYME CORPORATION (US) | 2013-01-30 | — | — | EP | disclosed |
| US-20100298317-A1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | GENZYME CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-20100298317-A1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | GENZYME CORPORATION | 2010-11-25 | — | — | US | disclosed |
| WO-2009045503-A1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | GENZYME CORPORATION (US) | 2009-04-09 | — | — | WO | disclosed |
| EP-0482080-B1 | SMALL CYCLIC PLATELET AGGREGATION INHIBITORS | GENENTECH INC (US) | 1997-03-26 | — | — | EP | disclosed |
| EP-0493506-A1 | CHIMERIC AMINO ACIDS AND PEPTIDES CONTAINING THESE ANALOGUES | GENENTECH, INC. (US) | 1992-07-08 | — | — | EP | disclosed |
| EP-0482080-A1 | SMALL CYCLIC PLATELET AGGREGATION INHIBITORS. | GENENTECH INC (US) | 1992-04-29 | — | — | EP | disclosed |
| WO-1991004247-A1 | CHIMERIC AMINO ACIDS AND PEPTIDES CONTAINING THESE ANALOGUES | GENENTECH, INC. (US) | 1991-04-04 | — | — | WO | disclosed |
| WO-1991001331-A1 | SMALL CYCLIC PLATELET AGGREGATION INHIBITORS | GENENTECH, INC. (US) | 1991-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150216872-A1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | SGMS1, SGMS2, CERS2 | HTR2C 4387/4885ALDH1A1 2203/4885MEN1 635/4885 |
| US-10220039-B2 | Method of treating polycystic kidney diseases with ceramide derivatives | SGMS1, SGMS2, CERS2 | HTR2C 4387/4885ALDH1A1 2203/4885MEN1 635/4885 |
| US-20170258802-A1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | SGMS1, SGMS2, CERS2 | HTR2C 4387/4885ALDH1A1 2203/4885MEN1 635/4885 |
| US-20100298317-A1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | SGMS1, SGMS2, CERS2 | HTR2C 4387/4885ALDH1A1 2203/4885MEN1 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.